Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Tvardi Therapeutics, Inc. (TVRD : NSDQ)

• Company Description    Tvardi Therapeutics Inc. is a privately held, clinical-stage, biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Tvardi Therapeutics Inc., formerly known as Cara Therapeutics Inc., is based in STAMFORD, Conn. Number of Employees: 10

• Price / Volume Information    Yesterday's Closing Price: $4.41 Daily Weekly Monthly 20 Day Moving Average: 110,450 shares Shares Outstanding: 9.38 (millions) Market Capitalization: $41.37 (millions) Beta: 0.11 52 Week High: $43.65 52 Week Low: $3.74 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 7.30% 5.89% 12 Week -88.62% -88.94% Year To Date -75.98% -79.16%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3 SUGAR CREEK CTR. BLVD. SUITE 525 - SUGAR LAND,TX 77478 USA ph: 713-489-8654 fax: 203-567-1510 ir@tvardi.com http://www.tvarditherapeutics.com

• General Corporate Information    Officers Christopher Posner - President; Chief Executive Officer Ryan Maynard - Chief Financial Officer Martin Vogelbaum - Director Jeffrey Ives - Director Lisa von Moltke - Director Peer Information Tvardi Therapeutics, Inc. (CORR.) Tvardi Therapeutics, Inc. (RSPI) Tvardi Therapeutics, Inc. (CGXP) Tvardi Therapeutics, Inc. (BGEN) Tvardi Therapeutics, Inc. (GTBP) Tvardi Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 140755307 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/10/26 Share - Related Items Shares Outstanding: 9.38 Most Recent Split Date: 4.00 (0.33:1) Beta: 0.11 Market Capitalization: $41.37 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.55 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.80 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/10/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.48 Price/Cash Flow: - Price / Sales: 3.72 EPS Growth vs. Year Ago Period: 89.08% vs. Previous Quarter: 41.00% Sales Growth vs. Year Ago Period: 20.33% vs. Previous Quarter: -48.64% ROE 09/30/25 - -282.16 06/30/25 - -698.66 03/31/25 - - ROA 09/30/25 - -82.03 06/30/25 - -82.37 03/31/25 - -117.73 Current Ratio 09/30/25 - 3.48 06/30/25 - 4.04 03/31/25 - 32.48 Quick Ratio 09/30/25 - 3.48 06/30/25 - 4.04 03/31/25 - 31.73 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - -546.92 Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - -585.37 Pre-Tax Margin 09/30/25 - -453.67 06/30/25 - -339.02 03/31/25 - -409.02 Book Value 09/30/25 - 2.97 06/30/25 - 3.52 03/31/25 - -2.59 Inventory Turnover 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - - Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - -

Powered by Zacks Investment Research ©